tldrdailynews.com logo
Tag

Tirzepatide

All articles tagged with #tirzepatide

Genes influence GLP-1 weight-loss drug responses and side effects
health1 day ago

Genes influence GLP-1 weight-loss drug responses and side effects

Genetic differences, including a GLP1R variant and a GIPR variant, modestly affect how much weight people lose and their risk of nausea on GLP-1 obesity drugs; the weight-loss difference is small—about 1.7 lb more at eight months for one copy and ~3.3 lb for two copies. A GIPR variant was linked to higher nausea with tirzepatide. Separately, higher GLP-1 doses may confer cardiovascular benefits that seem independent of weight loss, suggesting dosing could optimize heart outcomes; tissue data indicate potential direct cardiac effects, warranting further study.

via Reuters|
#genetics#glp-1#health
DNA Clues Shed Light on Why GLP-1 Weight-Loss Varies
health1 day ago

DNA Clues Shed Light on Why GLP-1 Weight-Loss Varies

A large 23andMe GWAS of 27,885 GLP-1 med users links variants in GLP1R and GIPR to both weight-loss efficacy and nausea risk. A GLP1R missense variant (rs10305420) is associated with about 0.76 kg more weight loss per allele, while GIPR variants predict nausea specifically for tirzepatide (Zepbound/Mounjaro) but not semaglutide. 23andMe’s Total Health service now offers an interactive tool to estimate individual weight loss (roughly 6–20% of starting weight) and side-effect risk, moving toward precision obesity care where genetics is one piece of the puzzle though not the sole determinant.

via Neuroscience News|
#genetics#glp-1#health
Genetic variants forecast GLP-1 weight‑loss response and nausea risk
science3 days ago

Genetic variants forecast GLP-1 weight‑loss response and nausea risk

A large GWAS in 23andMe participants identifies a GLP1R missense variant (rs10305420) linked to greater weight loss from GLP‑1 receptor agonists (~0.76 kg per allele) and links GLP1R and GIPR variants to treatment‑related nausea/vomiting, with a tirzepatide‑specific GIPR signal; replication in All of Us EHR data and integrated predictive models show that combining genetic and non‑genetic factors can stratify patients by efficacy and side‑effect risk, advancing precision obesity treatment.

via Nature|
#gipr#glp1r#obesity
Hormone Therapy May Boost GLP-1 Weight-Loss Drugs in Postmenopausal Women
health12 days ago

Hormone Therapy May Boost GLP-1 Weight-Loss Drugs in Postmenopausal Women

A retrospective study of 120 postmenopausal women found that adding menopausal hormone therapy to tirzepatide led to about 19.2% total body weight loss over roughly 18 months, versus 14% with tirzepatide alone, a statistically significant difference. The study is not randomized and did not distinguish hormone therapy types; researchers say controlled trials are needed to confirm the potential synergy and to explore cardiometabolic effects, building on prior work suggesting similar benefits with other GLP-1 drugs plus hormone therapy.

via ScienceAlert|
#glp-1#health#menopausal-hormone-therapy
Real-World Data Show Minimal Weight Regain After Stopping GLP-1 Obesity Drugs
health23 days ago

Real-World Data Show Minimal Weight Regain After Stopping GLP-1 Obesity Drugs

A Cleveland Clinic study of nearly 8,000 adults who stopped GLP-1 medications (such as Ozempic or tirzepatide) found only modest weight regain after one year (average 0.5%), suggesting real-world outcomes may diverge from clinical trials. Many patients either stay on some form of obesity treatment or switch to alternatives, with weight loss largely maintained when ongoing care and lifestyle support are in place, though results vary across populations and settings.

via Fox News|
#glp-1#health#ozempic
Most weight lost on GLP-1 obesity drugs returns within a year, study finds
health25 days ago

Most weight lost on GLP-1 obesity drugs returns within a year, study finds

A meta-analysis of six randomized trials (3,200+ participants) shows people rapidly regain about 60% of the weight lost during GLP-1 class obesity treatments within a year of stopping, with long-term modelling suggesting regain may plateau after around 60 weeks and reach roughly 75% of the lost weight. The studies raise uncertainty about whether regained weight is lean mass or fat, and they underscore the potential need for tapering doses and lifestyle support to preserve fat loss after cessation.

via ScienceAlert|
#glp-1#health#obesity-drugs
Lilly warns of unknown safety risks in tirzepatide-B12 compounded drugs
health1 month ago

Lilly warns of unknown safety risks in tirzepatide-B12 compounded drugs

Eli Lilly issued a public warning about potential patient safety risks from compounded tirzepatide mixed with vitamin B12, including a newly identified impurity with unknown short- and long-term effects. The company says these compounded tirzepatide-B12 products lack safety monitoring and adverse-event reporting, has alerted the FDA, and urges patients to discuss alternatives with their physicians. Lilly also cautions about broader safety issues and contaminants in other unregulated tirzepatide knockoffs and calls for regulator action to curb mass compounding in favor of FDA-approved therapies like Mounjaro and Zepbound.

via Eli Lilly|
#compounded-drugs#fda#health
GLP-1 medications show broad potential to curb multiple addictions
health1 month ago

GLP-1 medications show broad potential to curb multiple addictions

A BMJ study analyzing VA records of over 600,000 adults with type 2 diabetes found that GLP-1 drugs (such as semaglutide and tirzepatide) were associated with fewer emergency visits, hospitalizations, and deaths related to substance use across alcohol, opioids, nicotine, and other drugs. Using emulated target trials, researchers suggest GLP-1s might help treat existing substance use disorders and potentially prevent new ones, possibly by dampening reward signaling in the brain. However, these are observational analyses, not randomized trials, and results may not apply to everyone; further trials are underway, with relapse and varied efficacy remaining challenges.

via NBC News|
#addiction#glp-1#health
Novo Nordisk stock slides after CagriSema misses non-inferiority vs Lilly’s tirzepatide
business1 month ago

Novo Nordisk stock slides after CagriSema misses non-inferiority vs Lilly’s tirzepatide

Novo Nordisk’s stock fell about 15% after its weight‑loss candidate CagriSema failed to demonstrate non‑inferiority to Eli Lilly’s tirzepatide over 84 weeks (23% weight loss on CagriSema vs 25.5% for tirzepatide at 84 weeks). Lilly’s drug remains dominant in the market, and Novo is pursuing higher‑dose trials while facing competition, U.S. price pressure, and looming loss of exclusivity for Wegovy and Ozempic. The stock traded at its lowest since June 2021, and Lilly stock rose in premarket trading as Novo cautioned about slower growth in 2026.

via CNBC|
#business#cagrisema#novonordisk
Tirzepatide reduces alcohol reward in rodent study, hinting at AUD therapy
science1 month ago

Tirzepatide reduces alcohol reward in rodent study, hinting at AUD therapy

Rodents treated with tirzepatide (Mounjaro) drank more than half as much alcohol as controls, showed fewer relapse-like drinking episodes, and exhibited reduced alcohol-induced dopamine spikes in the brain’s reward center, the lateral septum. The drug also altered histone-related proteins, suggesting possible long-term neural changes. While promising, human trials are needed to confirm efficacy for alcohol use disorder, though tirzepatide’s established safety profile could speed future research.

via Neuroscience News|
#alcohol-use-disorder#dopamine#glp-1gip-dual-agonist
Novo Nordisk Slips on 2026 Sales Outlook Amid Ozempic/Wegovy Pressure
business2 months ago

Novo Nordisk Slips on 2026 Sales Outlook Amid Ozempic/Wegovy Pressure

Novo Nordisk beat 2025 sales estimates but warned that 2026 sales will fall 5%–13% at constant exchange rates, reversing last year’s growth. The drop is driven by expected weaker U.S. sales amid competition from Lilly’s tirzepatide and pricing pressures under MFN reforms, even as international sales may rise with Wegovy expanding into more markets. The outlook sent the stock lower, with U.S.-listed shares sliding about 14% after the report.

via Barron's|
#2026-sales-decline#business#novo-nordisk
UK reports triple-digit rise in Mounjaro side effects in 2025, with 71 deaths
health2 months ago

UK reports triple-digit rise in Mounjaro side effects in 2025, with 71 deaths

UK health chiefs recorded 40,245 adverse reactions to the diabetes/weight-loss jab Mounjaro in 2025 (6,755 serious; 71 deaths), a roughly 340% rise from 2024. Gastrointestinal disorders were the most common reaction (37,546 reports, 19 fatal). The NHS notes symptoms like nausea and diarrhea, while patients report severe side effects. Eli Lilly says safety is a priority and that risks are monitored. The MHRA updated product info to include a small risk of severe acute pancreatitis for Mounjaro (as well as Wegovy and Ozempic). Regulators stress benefits often outweigh risks, and urge patients to consult doctors about side effects. In the UK, around 1.6 million people are said to have used these lipids-lowering injections in the past year.

via Daily Mail|
#adverse-effects#health#mhra
GLP-1 Drugs in 2026: A Practical Guide to Today’s Options and the Pipeline
health2 months ago

GLP-1 Drugs in 2026: A Practical Guide to Today’s Options and the Pipeline

An up-to-date primer on GLP-1 therapies through 2026, detailing approved drugs (Ozempic, Wegovy, Rybelsus, Mounjaro/Zepbound, Victoza/Saxenda, Trulicity, Byetta/Bydureon, Adlyxin/Lyxumia) and promising ones (orforglipron, retatrutide), their dosing (daily vs weekly), diabetes vs obesity uses, and safety notes (thyroid tumor risk), plus the state of generics and the 2026 pipeline.

via New York Post|
#diabetes#glp-1#health